# Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

> **NCT05107882** · — · COMPLETED · sponsor: **Optina Diagnostics Inc.** · enrollment: 466 (actual)

## Conditions studied

- Alzheimer Disease
- Mild Cognitive Impairment
- Mild Dementia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05107882
- **Lead sponsor:** Optina Diagnostics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-07
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-07-25
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107882, "Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05107882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*